INTRODUCTION
The COVID-19 infection is now confirmed approximately 6 million worldwide, and over 1.7 million in the United States (1). Acute thrombotic events can occur during admission of COVID-19 (2). Among patients with severe COVID-19 symptom admitted to ICU, high incidence of venous thromboembolism has been reported despite prophylaxis (3). Patients who developed acute respiratory distress syndrome (ARDS) associated with COVID-19 showed significantly higher incidence of pulmonary embolism compared to ARDS without COVID-19 (4). However, data of hypercoagulability is still not available post-discharge after recovering from COVID-19 ARVD (5).